Social networks
2,855Activities
Technologies
Entity types
Location
1015 Lausanne, Switzerland
Lausanne
Switzerland
Employees
Scale: 2-10
Estimated: 20
Engaged corporates
3Added in Motherbase
3 months, 1 week agoTargeting the root cause of neurodegeneration
Asceneuron is a clinical stage biotech company focused on the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical need. The pipeline reflects our ambition to develop treatments for a wide a range of neurodegenerative diseases including orphan tauopathies, Alzheimer’s and Parkinson’s disease. Asceneuron has two clinical stage small molecule O-GlcNAcase inhibitors in development for the treatment of proteinopathies including Parkinson’s Disease, Alzheimer’s disease and related disorders.
Asceneuron is a privately held company financed by a renowned syndicate of investors consisting of Sofinnova Partners, M Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. For more information, please visit www.asceneuron.com.
Further information: www.asceneuron.com
Orphan Diseases, Tauopathies, Alzheimer's disease, Small Molecule Drug Discovery, Neurodegeneration, Novel Therapeutics, PSP, Parkinson's disease, and Biotechnology
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
Sofinnova Partners Financial Services | Sofinnova Partners Financial Services | Other 21 Jul 2024 | | |
GSK Pharmaceutical, Pharmaceutical Manufacturing | GSK Pharmaceutical, Pharmaceutical Manufacturing | Other 21 Jul 2024 | | |
EPFL Innovation Park Startup accelerator & VC, Professional Training and Coaching | EPFL Innovation Park Startup accelerator & VC, Professional Training and Coaching | Other 19 Jul 2024 | |